Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PJ019
- Development stage
- Preclinical
- Lead developer
- Chongqing Peg-Bio Biopharm
- Modality
- PEGylated Peptides → Modified Peptides → Peptides, Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
PJ019 is a pegylated recombinant human interleukin-11 (PEG-rhIL-11) being developed by Chongqing Peg-Bio Biopharm. It is intended for the treatment and prevention of chemotherapy-induced thrombocytopenia (CIT) in patients receiving myelosuppressive combined chemotherapy. Interleukin-11 (IL-11) is a pleiotropic cytokine and a thrombopoietic growth factor that stimulates the proliferation of hematopoietic stem cells and megakaryocyte progenitor cells, as well as the maturation of megakaryocytes, leading to increased peripheral platelet production. By attaching a polyethylene glycol (PEG) moiety to the recombinant protein, PJ019 achieves a prolonged half-life and improved pharmacokinetic profile compared to non-pegylated rhIL-11 (oprelvekin), potentially allowing for less frequent dosing and reduced immunogenicity.
- Other names
- pegylated recombinant human interleukin-11PEG-rhIL-11PEG-rhIL11PEG-rhIL 11聚乙二醇化重组人白介素-11
02
Targets
IL6ST (Interleukin-6 receptor subunit beta)IL11RA (Interleukin-11 receptor subunit alpha)
Beyond the preview
Go deeper on PJ019.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PJ019.